<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The growth characteristics and the prognostic value of cytokine-stimulated myeloid colony formation from peripheral blood mononuclear cells (PBMC) of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In this study we have determined the number of myeloid colony-forming units (mCFUs) in semisolid medium from 112 MDS patients and correlated them with French-American-British (FAB) type, the international prognostic scoring system (IPSS), karyotype, peripheral blood (PB) and bone marrow (BM) blast cells, cytopenias, <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH), and survival data </plain></SENT>
<SENT sid="2" pm="."><plain>Concerning the FAB classification, lower median mCFUs were found in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) compared to <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blast cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts cells in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro growth in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clearly correlated with the cytogenetic risk groups defined by the IPSS (30.5/10(5) PBMCs with favorable karyotypes, 191 in the intermediate prognostic group, 677 with unfavorable cytogenetics, p=0.015 favorable vs unfavorable) </plain></SENT>
<SENT sid="4" pm="."><plain>BM blast cells &gt;5% (60.5 vs 255 colonies, p=0.032) as well as LDH levels above the <z:mpath ids='MPATH_458'>normal</z:mpath> limit (64.5 vs 425 colonies, p=0.045) were also associated with higher colony formation </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were stratified according to the number of circulating mCFUs into a low growth, intermediate growth and high growth group </plain></SENT>
<SENT sid="6" pm="."><plain>Median survival was 343 days in the high growth, 1119 days in the low growth, and 2341 days in the intermediate growth group ( p=0.0002) </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analyses revealed colony growth ( p=0.0056), PB blast cells ( p=0.0069), cytogenetic risk group ( p=0.024), and platelet count ( p=0.018) to predict survival in our patients </plain></SENT>
<SENT sid="8" pm="."><plain>After inclusion of the IPSS risk categories, mCFU levels remained a highly predictive parameter for survival ( p=0.0056) and <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformation ( p=0.0003) </plain></SENT>
</text></document>